28 results about "Adenosine monophosphate" patented technology

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The present application belongs to the technical field of biological fermentation and discloses a process for the production of L-histidine by biological fermentation. It comprises the following steps: inoculating a seed solution of Escherichia coli into a fermenter containing a fermentation medium at a culture temperature of 35-37°C, maintaining the reducing sugar content at 46 g / L by adding a glucose solution containing adenosine monophosphate in fed-batch increments, stopping the addition of the glucose solution 4 hours before the end of fermentation, maintaining the pH in the fermenter at 6.9-7.1 by adding ammonia solution in fed-batch increments, and adding an antifoaming agent to control foaming, with the fermentation time being 40-50 hours, thereby obtaining an L-histidine fermentation solution.The process according to the present application exhibits high fermentation efficiency and low production costs and is suitable for industrial production.

Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) is an enzyme sensor of double-stranded DNA (dsDNA) that serves to trigger activation of the cGAS-stimulator of interferon genes (STING) pathway. The inhibition of cGAS with Cladophorol A is described herein.

The invention discloses an application of lactobacillus delbrueckii subsp. Lactis ABSN20244504 and a metagen thereof in preparation of a product for inhibiting skin light injury, and relates to the technical field of microorganisms, the preservation number of the strain is CGMCC No.34743, and the strain is separated from traditional fermented yak yoghourt in the Alba plateau in Sichuan of China and has good capability of tolerating artificial gastric acid and cholate in vitro. The invention also discloses an application of the strain and the inactivated metagen thereof in preparation of a product for inhibiting skin light injury. Animal experiments show that the mouse skin injury induced by ultraviolet B can be obviously relieved whether the viable bacteria of the strain are orally taken or locally smeared with inactivated postbiotics of the strain, and the action mechanism of the strain is related to oxidative stress relieving, inflammatory reaction inhibiting, AMPK (adenosine monophosphate kinase) adjusting and other related signal channels. The invention provides a new strain resource and an application strategy for developing a novel oral probiotic preparation and an external cosmetic for preventing and repairing skin light injury.

The invention relates to the technical field of biological medicines, and particularly discloses application of adenosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the adenosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the adenosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of adenosine monophosphate is shown in the specification.

The application provides a uridine monophosphate specific glycoside hydrolase and application thereof in biosynthetic synthesis of pseudouridine. Nmygdh The function of the gene is verified by in-vitro enzyme activity experiment Nmygdh The recombinant protein has broad-spectrum and high-efficiency catalytic activity, and can efficiently catalyze the hydrolysis of glycosidic bonds in various nucleotides, such as uridine monophosphate (UMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP) and cytidine monophosphate (CMP), and the activity of uridine monophosphate is the strongest. The application uses the protein to efficiently hydrolyze uridine monophosphate to obtain two substrates of pseudouridine, i.e. uracil and 5'-phosphoribose, and realizes the atom-economical and efficient biosynthetic synthesis of pseudouridine by combining the cascade reaction of pseudouridine glycosidase EcPsuG and dephosphorylase EcYjjG.

The invention belongs to the technical field of biological detection and analysis, and particularly relates to an adenosine phosphate photoaffinity probe as well as a preparation method and application thereof. The probe comprises an AMP-N (adenosine monophosphate-N) photoaffinity probe, an ADP-N (adenosine monophosphate-N) photoaffinity probe and an ATP-N (adenosine monophosphate-N) photoaffinity probe, the phosphoric acid part of adenosine monophosphate is modified with a photoaffinity group diaziridine with a small volume and alkynyl capable of carrying out a biological orthogonal reaction, and a connecting bond capable of cracking under an acidic condition is designed between adenosine monophosphate and a photoreactive group. The probe is high in stability and good in marking efficiency, can specifically mark the adenosine phosphate binding protein and identify the binding site of the adenosine phosphate binding protein, is suitable for screening, functional research and affinity analysis of the adenosine phosphate binding protein and discovery and verification of related drug targets, and has a wide application prospect.

The application discloses a cyclic GMP-AMP synthetase mutant and a method for preparing 2',3'-cyclic guanosine monophosphate-adenosine monophosphate by using the cyclic GMP-AMP synthetase mutant, wherein the amino acid sequence of the cyclic GMP-AMP synthetase mutant has any one of the following mutations: P361A, L377M, K432R, S221Y / F357L / I496V, S221L / Y248F / K432H / S434T, F357L / P361A / L377M / S434T, F357L / P361A / S434T / H437T or H437T / S434T, compared with a wild type as shown in SEQ ID NO. 1. The activity of the cGAS mutant of the application can reach 4 times of the wild type, raw materials of the preparation method are economical and easy to obtain, the operation is simple, green, environment-friendly, pollution-free, the synthesis efficiency is high, and industrial development is easy.

This method and composition involves oral administration of a low dose of D-ribose to enhance adenosine monophosphate-activated protein kinase (AMPK) activity in both exercising and sedentary mammals, improve mitochondrial-related oxidative metabolic parameters, and thereby promote overall metabolic health in mammals.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and / or for treating or preventing an AMPK-associated disease or condition in a subject.

The invention provides application of herpetonol in preparation of a medicine for treating or / and preventing fatty liver diseases. According to the invention, through a mouse model established by high fat diet (HFD) and a cell model induced by free fatty acid (FFA), the influence of herpetolol (HPO) on metabolic dysfunction related fatty liver disease (MASLD) is researched. In addition, through a drug affinity reaction target spot stability experiment (DARTS) and a cell thermal displacement experiment (CETSA), a key target spot of the action of the HPO and an action mechanism of the HPO are identified. Research finds that in an MASLD mouse model, the treatment of the hernol (HPO) significantly alleviates the lipid accumulation and inflammatory infiltration of the liver, and reveals that the hernol directly targets an adiponectin receptor 1 (ADIPOR1), up-regulates the expression of the ADIPOR1, activates an adenylate activated protein kinase (AMPK) pathway and further inhibits the nucleation regulation of sterol regulatory element binding protein 1c (SREBP-1c), thereby providing a potential direction for the treatment strategy of the MASLD.

The invention discloses a method for visually detecting various phosphates, which comprises the following steps: firstly, synthesizing three MOF (Metal Organic Framework) nano-enzymes, namely PCN-222 (Fe), PCN-223 (Fe) and PCN-224 (Fe) with peroxidase-like activity, catalyzing a colorless substrate 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) into oxTMB in a blue oxidation state by the three MOF nano-enzymes in the presence of H2O2, and generating remarkable colorimetric response; then, the five phosphates, namely ATP (adenosine triphosphate), ADP (adenosine diphosphate), AMP (adenosine monophosphate), PPi (pyrophosphoric acid) and Pi (inorganic phosphate), are simultaneously distinguished and detected by utilizing the principle that different phosphates have different regulation degrees on the peroxidase-like activity of the MOF nano-enzyme. In combination with a smartphone application program 'ColorMax', real-time visual analysis of phosphate is realized, and an efficient and convenient method is provided for distinguishing and detecting different phosphates.

The invention discloses application of sodium bicarbonate in preparation of a medicine for enhancing anti-tumor immunity. The molecular formula of the sodium bicarbonate is NaHCO3. Sodium bicarbonate can enhance natural immunity and acquired immunity of tumor resistance, and is characterized by including but not limited to activation of a cyclic guanylate-adenylate synthetase (cGAS)-interferon gene stimulating factor (cGAS-STING) signal channel in tumor cells, promotion of infiltration of immune cells in tumors and enhancement of the antitumor efficacy of the immune checkpoint inhibitor.

The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).

This invention provides peptides with anti-obesity and / or anti-diabetic activity, composed of the amino acid sequence of Sequence 1 or Sequence 2. These peptides inhibit fat accumulation, reduce the size of adipocytes, and increase the expression of phosphorylated hormone-sensitive lipase, adenosine monophosphate-activated protein kinase-α1, and comparative gene recognition-58 (CGM-58), which are lipolysis factors, thereby breaking down accumulated fat. This not only exhibits excellent anti-obesity effects but also effectively reduces blood glucose levels, increasing the expression of adiponectin and adenosine monophosphate-activated protein kinase (CGM-58), which improve insulin resistance; increasing the expression of glucose transporter protein 4 (a glucose transport channel); and increasing the expression of insulin receptor substrate-1 (an insulin receptor signaling protein), thus exhibiting excellent effects against diabetes. The peptides of this invention can be effectively used in the prevention or treatment of obesity and / or diabetes.

The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).

The invention discloses a novel application of an AMPK (adenosine monophosphate kinase) activator Aldometanib in preparation of a medicine for inhibiting inflammatory pain. The research finds that animal experiments prove that the AMPK activator Aldometanib can obviously activate p-AMPK, effectively relieve inflammatory pain, improve the pain threshold value and relieve inflammation, and is high in safety, wide in application range and free of obvious side effects. The invention also discloses a molecular mechanism of the Aldometanib for relieving pain, and finds that the Aldometanib reduces the expression of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, IL-8 and the like by activating p-AMPK and regulating an STAT3-BDNF-TrkB pathway, and also reduces the activation of microglial cells, thereby reducing the damage and sensitization of nerve cells and playing a role in easing pain. The application of the Aldometanib in the field of medicine is expanded, a safe and effective treatment strategy is provided for treatment of inflammatory pain, and the application has wide clinical application prospects and market value.

The invention belongs to the technical field of biomarker sampling and stabilization, and particularly relates to a compound stabilizer for a blood sampling card, which comprises the following components: a cell lysis agent, which is selected from guanidine, sodium dodecyl sulfate, quaternary ammonium salt or polyquaternary ammonium salt and has a concentration of 1-5%; the NAD < + > metabolic enzyme inhibitor is selected from nicotinamide riboside, apigenin or ABT-888, and the concentration of the NAD < + > metabolic enzyme inhibitor is 0.1-1.0 mM; the NAD < + > degradation product is selected from adenosine diphosphate ribose, adenosine monophosphate, nicotinamide mononucleotide or nicotinamide, and the concentration of the NAD < + > degradation product is 0.1-1.0 mM; the pH stabilizer is selected from citric acid or EDTA (Ethylene Diamine Tetraacetic Acid), and the concentration of the pH stabilizer is The materials used in the formula are all common chemical reagents in the market, are low in toxicity, green and safe, and are simple in preparation and smearing process and suitable for industrial production.

This invention discloses a compound taste-masking composition for leech decoction, the taste-masking leech decoction, its preparation method, and its application, belonging to the field of traditional Chinese medicine pharmaceutical technology. This invention provides a compound taste-masking composition composed of adenosine monophosphate (AMP), hydroxypropyl-β-cyclodextrin (HP-β-CD), and steviol glycosides, and provides its application method: first, HP-β-CD is added for inclusion and deodorization, then AMP and steviol glycosides are added to synergistically suppress bitterness. This combination utilizes a complementary strategy of "physical inclusion-receptor antagonism-taste neutralization" to simultaneously and efficiently mask the bitterness and fishy taste of leech decoction. Through orthogonal experimental optimization and verification using electronic tongue and sensory evaluation, the optimal formula (AMP 0.10%, HP-β-CD 0.50%, steviol glycosides 0.03%) reduces the bitterness score from 9.3 to 0.6 and the fishy taste score from 9.6 to 1.0. The method of this invention is performed at room temperature and pressure, is simple in process, does not affect the main active ingredients, is suitable for industrial production, and can significantly improve patients' compliance with leech decoction.

This invention relates to a multifunctional bio-based modifier, its preparation method, and its uses, belonging to the field of PLA composite materials. By weight, it comprises 10 parts adenosine monophosphate, 5-8 parts β-cyclodextrin, and 3-4 parts creatine. The preparation method includes the following steps: (1) adding 10 parts adenosine monophosphate and 4-5 parts of a 37%-40% formaldehyde aqueous solution to 200 parts of water, heating to 75-85℃, and reacting for 1-2 hours; (2) after the reaction, adding 5-8 parts β-cyclodextrin, heating to 80-100℃, and reacting for 2-3 hours; (3) finally adding 3-4 parts creatine, cooling to 45-55℃, and reacting for 1.5-2.5 hours. After filtration, washing, and drying, the multifunctional bio-based modifier is obtained. The multifunctional bio-based modifier of this invention can impart flame retardant, toughening, UV aging resistance, and recyclability to PLA at low addition levels, thus showing good industrial application prospects.

The application discloses a method for detecting H2O2 and glucose, and constructs an AMP-Tb / CPBA probe by using adenosine monophosphate (AMP), terbium (Tb) and 3-carboxyphenylboronic acid (CPBA). 3+ CPBA can open the fluorescence of Tb 3+ at 488 and 544 nm as a sensitizing agent. The probe can be used for quantitative detection of H2O2 and glucose, and the sensitivity and selectivity of the detection are good, and the detection limits of H2O2 and glucose can be as low as 0.23 μM and 0.49 μM respectively.

The present invention relates to compounds of Formulas I to IV, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).

The invention belongs to the technical field of biosynthesis, and relates to a multi-enzyme catalysis system and method for synthesizing functional glycans. The system comprises a substrate module comprising nucleoside monophosphate, monosaccharide, polyphosphate and acceptor molecules; the nucleoside monophosphoric acid is one or more of uridine monophosphoric acid, adenosine monophosphoric acid, guanosine monophosphoric acid or cytidine monophosphoric acid; an enzyme module comprising a polyphosphate kinase, at least one remedial pathway synthetase, and at least one glycosyltransferase; the cofactor module comprises magnesium ions and optional inorganic pyrophosphatase; the system can realize in-situ regeneration of sugar nucleotide with nucleoside monophosphate as an initial cofactor and one-pot synthesis of target glycan. The invention systematically proposes that cheap NMP is used as a unique or main starting cofactor to replace expensive NTP or NDP for in-situ regeneration of various sugar nucleotides for the first time. Cofactor cost can be reduced by dozens of times, and a foundation is laid for large-scale production of glycans.

A process of using biological fermentation to produce L-histidine, comprising the following steps: introducing an Escherichia coli seed solution into a fermentation tank containing a fermentation culture medium, the culture temperature ranging from 35°C to 37°C; adding a glucose solution containing adenosine monophosphate in a fed-batch manner to maintain the content of reducing sugar at 46 g / L, and stopping the fed-batch addition of the glucose solution 4 h before the end of fermentation; and adding ammonia water in the fed-batch manner to maintain the pH value in the fermentation tank at 6.9 to 7.1, adding a defoamer in the fed-batch manner to perform defoaming, the fermentation time being 40 h to 50 h, and obtaining an L-histidine fermentation broth. The process has high fermentation efficiency and low production costs, and is suitable for industrial production.

The application discloses application of a 5'-monophosphate nucleotide composition in preparation of anti-aging and longevity drugs and / or functional foods, and belongs to the technical field of medicines.The composition is composed of 5'-monophosphate adenosine, 5'-monophosphate cytidine, 5'-guanylic acid disodium, 5'-uridylic acid disodium and hypoxanthine nucleotide, and the mass ratio of the acid types of CMP, AMP, UMP, GMP and IMP is respectively as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0 or greater than 0 and not higher than 2.5%. The composition can synergistically enhance various mechanisms such as significantly reducing an insulin resistance index, enhancing body anti-coagulation function, improving blood circulation, regulating metabolism of essential minerals such as lithium and copper and regulating intestinal flora ecology, delays aging and prolongs healthy life span. Animal experiment data show that, compared with a control group, the composition prolongs the median survival time of mice by 9.21-12.6%, and the equivalent human life span is 8.76-12.01 years. Human experiment data show that, compared with the control group, the composition intervention reduces the median age of DNA methylation by 3.08 years, and provides a new idea for developing anti-aging and longevity drugs and / or functional foods.